AR078169A1 - Formulaciones de vacunas que comprenden adyuvantes con saponina - Google Patents
Formulaciones de vacunas que comprenden adyuvantes con saponinaInfo
- Publication number
- AR078169A1 AR078169A1 ARP100103323A ARP100103323A AR078169A1 AR 078169 A1 AR078169 A1 AR 078169A1 AR P100103323 A ARP100103323 A AR P100103323A AR P100103323 A ARP100103323 A AR P100103323A AR 078169 A1 AR078169 A1 AR 078169A1
- Authority
- AR
- Argentina
- Prior art keywords
- ethoxylated
- sorbitan
- ionic surfactant
- hydrophilic
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 15
- 239000000194 fatty acid Substances 0.000 abstract 15
- 229930195729 fatty acid Natural products 0.000 abstract 15
- 150000004665 fatty acids Chemical class 0.000 abstract 13
- 239000002736 nonionic surfactant Substances 0.000 abstract 9
- 150000002148 esters Chemical class 0.000 abstract 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 6
- 230000002163 immunogen Effects 0.000 abstract 4
- -1 sorbitan triesters Chemical class 0.000 abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 abstract 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 abstract 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 abstract 2
- 206010026749 Mania Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 2
- 229920001400 block copolymer Polymers 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 abstract 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 150000002191 fatty alcohols Chemical class 0.000 abstract 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract 2
- 239000002563 ionic surfactant Substances 0.000 abstract 2
- 229940070765 laurate Drugs 0.000 abstract 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 2
- 229940049964 oleate Drugs 0.000 abstract 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical class FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 abstract 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical group CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 abstract 1
- 241001533384 Circovirus Species 0.000 abstract 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 abstract 1
- 239000005662 Paraffin oil Substances 0.000 abstract 1
- 241001661006 Pepper cryptic virus 2 Species 0.000 abstract 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 abstract 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 239000000287 crude extract Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 150000005691 triesters Chemical class 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una emulsion de aceite en agua (Ac/Ag), con mayor estabilidad en la presencia de suspensiones bacterianas o virales, en especial las que son concentradas y no purificadas (extractos crudos) o mínimamente purificadas. La emulsion de la presente puede actuar como vehículo para la administracion de una composicion farmacéutica que comprende al menos un inmunogeno y, en particular, un inmunogeno seleccionado del grupo que consiste de un patogeno inactivado, un patogeno atenuado, una subunidad, un vector de expresion recombinante y un plásmido o combinaciones de los mismos. Reivindicacion 1: Una composicion de vacuna que comprende una emulsion de aceite en agua (Ac/Ag) inyectable, caracterizada porque comprende: (i) una solucion acuosa que comprende al menos un inmunogeno; (ii) una solucion acuosa que comprende un agente tensioactivo ionico hidrofílico; (iii) una solucion acuosa opcional que comprende hidroxido de aluminio; (iv) un aceite mineral; (v) un agente tensioactivo no ionico lipofílico; (vi) un agente tensioactivo no ionico hidrofílico que tiene un valor alto de equilibrio hidrofilico-lipofílico (HLB) de entre 13 y 40; y (vii) un agente tensioactivo no ionico hidrofílico que tiene un valor bajo de equilibrio hidrofílico-lipofílico (HLB) de entre 9 y 13. Reivindicacion 2: La composicion de la reivindicacion 1, caracterizada porque el agente tensioactivo ionico hidrofílico es sapona y en donde la concentracion de la saponina es de entre aproximadamente 0,35 mg/dosis y aproximadamente 3,0 mg/dosis y en donde la concentracion de hidroxido de aluminio es de entre aproximadamente 0% y aproximadamente 1,0% (p/v). Reivindicacion 7: La composicion de la reivindicacion 2, caracterizada porque el agente tensioactivo no ionico hidrofílico con un valor bajo de HLB se selecciona del grupo que consiste de triésteres de ácidos grasos y sorbitán etoxilados, diésteres de ácidos grasos y sorbitán etoxilados, monoésteres de ácidos grasos y sorbitán etoxilados, alcoholes grasos etoxilados, ácido grasos etoxilados, aceite de ricino etoxilado y combinaciones de los mismos, y en donde el éster de dicho éster de ácido graso etoxilado se selecciona del grupo que consiste de oleato, palmitato, estearato, isoestearato, laurato y combinaciones de los mismos. Reivindicacion 8: La composicion de la reivindicacion 2, caracterizada porque el agente tensioactivo no ionico lipofílico se selecciona del grupo que consiste de ésteres de ácidos grasos y sorbitán, ésteres de ácidos grasos y manida, ésteres de ácidos grasos y manida dietoxilados, ésteres de ácidos grasos y manida trietoxilados, ésteres de ácidos grasos y manida tetraetoxilados y combinaciones de los mismos, y en donde el éster de los ésteres de ácidos grasos se seleccionan del grupo que consiste de oleato, palmitato, estearato, isoestearato, laurato y combinaciones de los mismos. Reivindicacion 9: La composicion de la reivindicacion 2, caracterizada porque el agente tensioactivo no ionico hidrofílico con valor alto de HLB se selecciona del grupo que consiste de monoésteres de ácidos grasos y sorbitán etoxilados, alcoholes grasos etoxilados, ácido grasos etoxilados, copolímeros de bloques no ionicos y combinaciones de los mismos, y en donde el monoéster de sorbitán etoxilado se selecciona del grupo que consiste de monolaurato de sorbitán etoxilado, monopalmitato de sorbitán etoxilado, monoestearato de sorbitán etoxilado, monooleato de sorbitán etoxilado y combinaciones de los mismos. Reivindicacion 11: La composicion de la reivindicacion 2, caracterizada porque comprende un aceite de parafina, un monoéster de ácido graso y sorbitán como un agente tensioactivo no ionico lipofílico, un triéster de ácido graso y sorbitán etoxilado como agente tensioactivo no ionico hidrofílico con un valor bajo de HLB y un copolímero de bloques no ionicos como agente tensioactivo no ionico hidrofílico con un valor alto de HLB. Reivindicacion 16: La composicion de la reivindicacion 15, caracterizada porque el inmunogeno es un virus de la enfermedad de fiebre aftosa (FMD) inactivado, un virus de circovirus tipo 2 porcino (PCV-2) inactivado o una bacteria Mycoplasma hyopneumoniae inactivada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24117109P | 2009-09-10 | 2009-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078169A1 true AR078169A1 (es) | 2011-10-19 |
Family
ID=43063042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103323A AR078169A1 (es) | 2009-09-10 | 2010-09-10 | Formulaciones de vacunas que comprenden adyuvantes con saponina |
| ARP210100138A AR121096A2 (es) | 2009-09-10 | 2021-01-21 | Formulaciones de vacunas que comprenden adyuvantes con saponina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100138A AR121096A2 (es) | 2009-09-10 | 2021-01-21 | Formulaciones de vacunas que comprenden adyuvantes con saponina |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9107859B2 (es) |
| EP (1) | EP2475384B1 (es) |
| JP (1) | JP5759463B2 (es) |
| KR (1) | KR101746880B1 (es) |
| CN (2) | CN102573900B (es) |
| AR (2) | AR078169A1 (es) |
| AU (1) | AU2010292233B2 (es) |
| BR (1) | BR112012005518B1 (es) |
| CA (1) | CA2773486C (es) |
| CO (1) | CO6531435A2 (es) |
| CY (1) | CY1119052T1 (es) |
| DK (1) | DK2475384T3 (es) |
| ES (1) | ES2600929T3 (es) |
| HR (1) | HRP20161414T1 (es) |
| HU (1) | HUE030664T2 (es) |
| LT (1) | LT2475384T (es) |
| MX (2) | MX344863B (es) |
| MY (1) | MY157607A (es) |
| NZ (1) | NZ598645A (es) |
| PL (1) | PL2475384T3 (es) |
| PT (1) | PT2475384T (es) |
| RU (1) | RU2555342C2 (es) |
| SG (1) | SG179037A1 (es) |
| SI (1) | SI2475384T1 (es) |
| SM (1) | SMT201600394B (es) |
| UA (1) | UA107940C2 (es) |
| WO (1) | WO2011031850A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120909A1 (es) * | 2009-05-19 | 2012-08-19 | Bioproperties Pty Ltd | Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma |
| CN102648003B (zh) * | 2009-10-09 | 2016-01-13 | 儿童医疗中心有限公司 | 选择性裂解的全细胞疫苗 |
| CN102226153B (zh) * | 2011-05-10 | 2012-12-05 | 黑龙江大学 | 用于生成污染菌抗血清的免疫原的制备方法 |
| CN108588035A (zh) * | 2011-06-28 | 2018-09-28 | 白血球保健股份有限公司 | 病毒或细菌的新型稳定方法 |
| AR089995A1 (es) | 2012-02-14 | 2014-10-01 | Merial Ltd | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas |
| RU2521513C1 (ru) * | 2013-04-09 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Применение этония в качестве адъюванта для производства сорбированной противоящурной вакцины |
| WO2014182872A1 (en) * | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
| WO2015179412A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (pedv) |
| SI3244920T1 (sl) * | 2015-01-16 | 2023-09-29 | The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture | Cepivo proti slinavki in parkljevki |
| CN104803850A (zh) * | 2015-04-29 | 2015-07-29 | 天津大学 | 一种酯类糖基相选择性亲油凝胶因子及其制备方法以及在油品胶凝中的应用 |
| US10617752B2 (en) | 2015-06-26 | 2020-04-14 | Boehringer Ingelheim Animal Health USA Inc. | Inactivated canine influenza vaccines and methods of making and uses thereof |
| EP3359187A1 (en) | 2015-10-08 | 2018-08-15 | Merial, Inc. | Live attenuated heterologous vaccine for leptospira |
| US9913891B2 (en) | 2015-11-23 | 2018-03-13 | Merial Inc. | FMDV and E2 fusion proteins and uses thereof |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| WO2017176950A2 (en) | 2016-04-07 | 2017-10-12 | Merial, Inc. | Heartworm vaccine, methods and uses thereof |
| JOP20190088A1 (ar) | 2016-10-21 | 2019-04-21 | Us Agriculture | نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها |
| KR20230170803A (ko) | 2016-12-14 | 2023-12-19 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 조류 병원체의 다중 항원을 발현하는 재조합 hvt 벡터 및 그를 포함하는 백신 |
| US11318199B2 (en) | 2017-05-31 | 2022-05-03 | Texas Tech University System | Methods and devices for the treatment of food allergies |
| CN109806391A (zh) * | 2017-11-22 | 2019-05-28 | 西北民族大学 | 一种兽用疫苗免疫水溶性复合佐剂的制备方法及其应用 |
| CN108853493A (zh) * | 2018-07-26 | 2018-11-23 | 中国人民解放军陆军军医大学 | 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用 |
| CN111658611B (zh) * | 2020-04-13 | 2021-06-01 | 四川大学 | 一种基于微乳的疫苗递送系统及其制备方法和应用 |
| BR102021012953A2 (pt) * | 2021-06-29 | 2023-01-10 | Fabp Biotech Desenvolvimento Em Biotecnologia Ltda. | Composição de vacina veterinária contra helmintos, método para tratamento e prevenção de infecção causada por helmintos e uso |
| US12036318B2 (en) * | 2022-02-16 | 2024-07-16 | Chemical & Schutz High Performance Lubricants, S.A. De C.V. | Self-emulsionable mineral oil as a vehicle in vaccines for poultry |
| CN117281899B (zh) * | 2022-06-24 | 2024-09-17 | 江苏瑞科生物技术股份有限公司 | 一种佐剂系统及其制备方法和应用 |
| CN116983396B (zh) * | 2023-08-09 | 2024-05-07 | 浙江省农业科学院 | 兔支气管败血波氏杆菌灭活疫苗乳剂及其制备和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2777608A (en) | 1953-09-18 | 1957-01-15 | Sheffler James | Soap powder dispenser attachment |
| GB1143545A (en) | 1965-03-25 | 1969-02-26 | Wellcome Found | Injectable vaccine emulsions |
| US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| CA1331443C (en) * | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| ES2112274T5 (es) | 1990-05-29 | 2006-03-01 | Wyeth Holdings Corporation | Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma. |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| WO1992018147A1 (en) * | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| US5846805A (en) | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
| JP3723231B2 (ja) * | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| ES2152304T3 (es) | 1993-02-08 | 2001-02-01 | Bayer Ag | Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas. |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
| US5866401A (en) | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
| US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| US6645495B1 (en) * | 1997-08-29 | 2003-11-11 | Antigenics, Inc. | Compositions of saponin adjuvants and excipients |
| CA2302554C (en) * | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| ES2296390T3 (es) | 1998-05-07 | 2008-04-16 | Corixa Corporation | Composicion coadyuvante y procedimiento para su uso. |
| TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
| NZ501264A (en) | 1998-12-22 | 2001-09-28 | Pfizer Prod Inc | Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS |
| US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| GB0009735D0 (en) | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
| MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| DE10113284A1 (de) | 2001-03-16 | 2002-10-02 | Heinrich Exner | Adjuvans-Emulsion und Verfahren zu deren Verwendung |
| AU2002367976B2 (en) * | 2001-06-05 | 2007-06-21 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| US6642178B2 (en) | 2001-11-14 | 2003-11-04 | North Dakota State University | Adjuvant blend for enhancing efficacy of pesticides |
| US7378101B2 (en) * | 2001-12-21 | 2008-05-27 | Pfizer, Inc. | Vaccine for periodontal disease |
| WO2005009462A2 (en) * | 2003-07-24 | 2005-02-03 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
| US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| JP5394750B2 (ja) * | 2005-12-29 | 2014-01-22 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | 多価ｐｃｖ２免疫原性組成物及び当該組成物を製造する方法 |
| WO2008076371A2 (en) * | 2006-12-15 | 2008-06-26 | Schering-Plough Ltd. | Method for replicating influenza virus in culture |
-
2010
- 2010-09-09 SI SI201031314A patent/SI2475384T1/sl unknown
- 2010-09-09 UA UAA201204469A patent/UA107940C2/ru unknown
- 2010-09-09 MX MX2014013363A patent/MX344863B/es unknown
- 2010-09-09 LT LTEP10757885.8T patent/LT2475384T/lt unknown
- 2010-09-09 RU RU2012113814/15A patent/RU2555342C2/ru active
- 2010-09-09 AU AU2010292233A patent/AU2010292233B2/en active Active
- 2010-09-09 KR KR1020127009114A patent/KR101746880B1/ko active IP Right Grant
- 2010-09-09 DK DK10757885.8T patent/DK2475384T3/en active
- 2010-09-09 HU HUE10757885A patent/HUE030664T2/en unknown
- 2010-09-09 CN CN201080047645.0A patent/CN102573900B/zh active Active
- 2010-09-09 SG SG2012016168A patent/SG179037A1/en unknown
- 2010-09-09 WO PCT/US2010/048256 patent/WO2011031850A1/en active Application Filing
- 2010-09-09 MY MYPI2012001035A patent/MY157607A/en unknown
- 2010-09-09 CA CA2773486A patent/CA2773486C/en active Active
- 2010-09-09 PL PL10757885T patent/PL2475384T3/pl unknown
- 2010-09-09 MX MX2012002814A patent/MX2012002814A/es active IP Right Grant
- 2010-09-09 JP JP2012528894A patent/JP5759463B2/ja active Active
- 2010-09-09 PT PT107578858T patent/PT2475384T/pt unknown
- 2010-09-09 ES ES10757885.8T patent/ES2600929T3/es active Active
- 2010-09-09 NZ NZ598645A patent/NZ598645A/en unknown
- 2010-09-09 EP EP10757885.8A patent/EP2475384B1/en active Active
- 2010-09-09 BR BR112012005518-6A patent/BR112012005518B1/pt active IP Right Grant
- 2010-09-09 US US12/878,630 patent/US9107859B2/en active Active
- 2010-09-09 CN CN201710382912.3A patent/CN107213461B/zh active Active
- 2010-09-10 AR ARP100103323A patent/AR078169A1/es not_active Application Discontinuation
-
2012
- 2012-04-10 CO CO12058153A patent/CO6531435A2/es unknown
-
2015
- 2015-02-26 US US14/632,863 patent/US9730987B2/en active Active
-
2016
- 2016-10-12 CY CY20161101013T patent/CY1119052T1/el unknown
- 2016-10-27 HR HRP20161414TT patent/HRP20161414T1/hr unknown
- 2016-11-03 SM SM201600394T patent/SMT201600394B/it unknown
-
2021
- 2021-01-21 AR ARP210100138A patent/AR121096A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078169A1 (es) | Formulaciones de vacunas que comprenden adyuvantes con saponina | |
| CA2533581A1 (en) | Vaccine formulations comprising an oil-in-water emulsion | |
| US11701415B2 (en) | Oil-based adjuvants | |
| JP2013504583A5 (es) | ||
| US7122191B2 (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
| JP2006522090A (ja) | マイクロ流動化された水中油形エマルジョン及びワクチン組成物 | |
| US20230052315A1 (en) | Vaccine adjuvant comprising an inverse microlatex | |
| GB888180A (es) | ||
| NL8004297A (nl) | Antigeenpreparaten. | |
| MY141874A (en) | Vaccine formulations comprising an oil-in-water emulsion | |
| ES2362828T3 (es) | Composición farmacéutica parenteral y su procedimiento de preparación. | |
| EP4138892A1 (en) | A vaccine to protect against mycoplasma hyopneumoniae | |
| CN118236480A (zh) | 油佐剂组合物和包含此类油佐剂组合物的疫苗乳剂 | |
| KR20110000259A (ko) | 고분자 유화제를 함유하는 안정성이 우수한 면역증강제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FC | Refusal |